Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
New Acridine-9-Carboxamide Linked to 1,2,3-Triazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors: Design, Synthesis, in Vitro, and in Silico Biological Evaluations Publisher



Sepehri N1 ; Asemanipoor N2 ; Mousavianfard SA3 ; Hoseini S4 ; Faramarzi MA4 ; Adib M3 ; Biglar M2 ; Larijani B2 ; Hamedifar H5 ; Mohammadikhanaposhtani M6 ; Mahdavi M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nano Alvand Company, Avicenna Tech Park, Tehran University of Medical Sciences, Tehran, 1439955991, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. School of Chemistry, College of Science, University of Tehran, PO Box 14155-6455, Tehran, Iran
  4. 4. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran
  6. 6. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

Source: Medicinal Chemistry Research Published:2020


Abstract

α-Glucosidase plays a major role in degradation of carbohydrates to glucose. Therefore, inhibition of this enzyme can be useful in the treatment of carbohydrate-related diseases such as diabetes, cancer, and viral infections. In this study, a new series of acridine-9-carboxamide linked to 1,2,3-triazole-N-phenylacetamide derivatives 5a–m were designed, synthesized, and evaluated as potent α-glucosidase inhibitors. All the synthesized compounds showed excellent to good inhibitory activity against α-glucosidase with IC50 values of 80.3 ± 0.9–564.3 ± 7.2 µM in comparison with standard drug acarbose (IC50 value = 750.0 ± 10.5 μM). Among the synthesized compounds, the most active compound was 3-bromo derivative 5h with inhibitory activity around 9.3 times more than acarbose. this compound was selected for farther biological evaluations. Kinetic study of compound 5h revealed that it is a competitive inhibitor against α-glucosidase. Docking study of compound 5h and its regioisomer 5i with 4-bromo substituent were also carried out in the active site of α-glucosidase to gain an insight into the interaction modes of the synthesized compounds and rationalized structure–activity relationship between these two compounds. Compound 5h was also evaluated against α-amylase and no activity was observed in comparison with acarbose. Furthermore, in vitro cytotoxic assay of compound 5h against human normal and cancer cell lines HDF and MCF-7, respectively, revealed that this compound is a noncytotoxic agent. In silico pharmacokinetic and toxicity assays of compound 5h was performed and obtained results were compared with acarbose. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Related Docs
View other Related Docs
1. Synthesis, in Vitro and in Silico Enzymatic Inhibition Assays, and Toxicity Evaluations of New 4,5-Diphenylimidazole-N-Phenylacetamide Derivatives As Potent Α-Glucosidase Inhibitors, Medicinal Chemistry Research (2021)
2. New Phthalimide-Benzamide-1,2,3-Triazole Hybrids; Design, Synthesis, Α-Glucosidase Inhibition Assay, and Docking Study, Medicinal Chemistry Research (2020)
3. A Review on Synthesis, Mechanism of Action, and Structure-Activity Relationships of 1,2,3-Triazole-Based Α-Glucosidase Inhibitors As Promising Anti-Diabetic Agents, Journal of Molecular Structure (2022)
4. Quinazolinone-Dihydropyrano[3,2-B]Pyran Hybrids As New Α-Glucosidase Inhibitors: Design, Synthesis, Enzymatic Inhibition, Docking Study and Prediction of Pharmacokinetic, Bioorganic Chemistry (2021)
5. Design and Synthesis of Novel Quinazolinone-1,2,3-Triazole Hybrids As New Anti-Diabetic Agents: In Vitro Α-Glucosidase Inhibition, Kinetic, and Docking Study, Bioorganic Chemistry (2019)
6. Design and Synthesis of Novel Quinazolinone-Pyrazole Derivatives As Potential Α-Glucosidase Inhibitors: Structure-Activity Relationship, Molecular Modeling and Kinetic Study, Bioorganic Chemistry (2021)
7. Synthesis, In-Vitro Evaluation, Molecular Docking, and Kinetic Studies of Pyridazine-Triazole Hybrid System As Novel Α-Glucosidase Inhibitors, Bioorganic Chemistry (2021)
8. Novel Aryl(4-Phenylpiperazin-1-Yl)Methanethione Derivatives As New Anti-Alzheimer Agents: Design, Synthesis, in Vitro and in Silico Assays, Journal of Molecular Structure (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Mahdavi (31)
Mohammad Ali Faramarzi (30)
Other Related Docs
9. Α-Glucosidase and Α-Amylase Inhibition, Molecular Modeling and Pharmacokinetic Studies of New Quinazolinone-1,2,3-Triazole-Acetamide Derivatives, Medicinal Chemistry Research (2021)
10. In Silico and in Vitro Studies of Thiosemicarbazone-Indole Hybrid Compounds As Potent Α-Glycosidase Inhibitors, Computational Biology and Chemistry (2022)
11. Synthesis and Biological Evaluation of New Dihydroindolizino[8,7-B]Indole Derivatives As Novel Α-Glucosidase Inhibitors, Journal of Molecular Structure (2021)
12. New Thiosemicarbazide-1,2,3-Triazole Hybrids As Potent Α-Glucosidase Inhibitors: Design, Synthesis, and Biological Evaluation, Journal of Molecular Structure (2019)
13. Design, Synthesis, in Vitro, and in Silico Studies of Novel Diarylimidazole-1,2,3-Triazole Hybrids As Potent Α-Glucosidase Inhibitors, Bioorganic and Medicinal Chemistry (2019)
14. Design, Synthesis, in Vitro, and in Silico Biological Evaluations of Coumarin-Indole Hybrids As New Anti-Α-Glucosidase Agents, BMC Chemistry (2022)
15. Design, Synthesis and in Vitro Α-Glucosidase Inhibition of Novel Dihydropyrano[3,2-C]Quinoline Derivatives As Potential Anti-Diabetic Agents, Bioorganic Chemistry (2018)
16. Synthesis, Molecular Dynamic, and in Silico Study of New Ethyl 4-Arylpyrimido[1,2-B]Indazole-2-Carboxylate: Potential Inhibitors of Α-Glucosidase, Journal of Molecular Structure (2022)
17. Synthesis of the New Tri-Amide Derivatives As Novel Α-Glucosidase Inhibitors by Ugi Four-Component Reaction, Journal of Molecular Structure (2021)
18. Pyrano[2,3-B]Chromone Derivatives As Novel Dual Inhibitors of Α-Glucosidase and Α-Amylase: Design, Synthesis, Biological Evaluation, and in Silico Studies, Bioorganic Chemistry (2024)
19. Design and Synthesis of Phenoxymethybenzoimidazole Incorporating Different Aryl Thiazole-Triazole Acetamide Derivatives As Α-Glycosidase Inhibitors, Molecular Diversity (2022)
20. 1-Phenyl-Β-Carboline-3-Carboxamide-1,2,3-Triazole-N-Phenylacetamide Hybrids As New Α-Glucosidase Inhibitors, Scientific Reports (2025)
21. Synthesis and Biological Evaluation of New Benzimidazole-1,2,3-Triazole Hybrids As Potential Α-Glucosidase Inhibitors, Bioorganic Chemistry (2020)
22. Docking Study, Molecular Dynamic, Synthesis, Anti-Α-Glucosidase Assessment, and Admet Prediction of New Benzimidazole-Schiff Base Derivatives, Scientific Reports (2022)
23. Design, Synthesis, and in Silico Studies of Benzimidazole Bearing Phenoxyacetamide Derivatives As Α-Glucosidase and Α-Amylase Inhibitors, Journal of Molecular Structure (2022)
24. Design, Synthesis Docking and Molecular Dynamics Studies of 2-Amino-4-Phenylthiazole-Indole Hybrids As Α-Glucosidase Inhibitors, Journal of Molecular Structure (2024)
25. 2,4-Dioxochroman Moiety Linked to 1,2,3-Triazole Derivatives As Novel Α-Glucosidase Inhibitors: Synthesis, in Vitro Biological Evaluation, and Docking Study, Current Organic Chemistry (2020)
26. Novel Coumarin Containing Dithiocarbamate Derivatives As Potent Α-Glucosidase Inhibitors for Management of Type 2 Diabetes, Medicinal Chemistry (2021)
27. Design and Synthesis of Novel Pyridazine N-Aryl Acetamides: In-Vitro Evaluation of Α-Glucosidase Inhibition, Docking, and Kinetic Studies, Bioorganic Chemistry (2020)
28. Synthesis, Α-Glucosidase Inhibitory Activity and Docking Studies of Novel Ethyl 1,2,3-Triazol-4-Ylmethylthio-5,6-Diphenylpyridazine-4-Carboxylate Derivatives, BMC Chemistry (2023)
29. Discovery of Novel 4,5-Diphenyl-Imidazol-Α-Aminophosphonate Hybrids As Promising Anti-Diabetic Agents: Design, Synthesis, in Vitro, and in Silico Enzymatic Studies, Bioorganic Chemistry (2023)
30. Design and Synthesis of 4,5-Diphenyl-Imidazol-1,2,3-Triazole Hybrids As New Anti-Diabetic Agents: In Vitro Α-Glucosidase Inhibition, Kinetic and Docking Studies, Molecular Diversity (2021)
31. Evaluation of Novel 2-(Quinoline-2-Ylthio)Acetamide Derivatives Linked to Diphenyl-Imidazole As Α-Glucosidase Inhibitors: Insights From in Silico, in Vitro, and in Vivo Studies on Their Anti-Diabetic Properties, European Journal of Medicinal Chemistry (2024)
32. Design and Synthesis of New Imidazo[1,2-B]Pyrazole Derivatives, in Vitro Α-Glucosidase Inhibition, Kinetic and Docking Studies, Molecular Diversity (2020)
33. Novel Pyrano[3,2-C]Quinoline-1,2,3-Triazole Hybrids As Potential Anti-Diabetic Agents: In Vitro Α-Glucosidase Inhibition, Kinetic, and Molecular Dynamics Simulation, ACS Omega (2023)
34. Imidazo[1,2-C]Quinazolines As a Novel and Potent Scaffold of Α-Glucosidase Inhibitors: Design, Synthesis, Biological Evaluations, and in Silico Studies, Scientific Reports (2023)
35. Design, Synthesis, in Vitro, and in Silico Enzymatic Evaluations of Thieno[2,3-B]Quinoline-Hydrazones As Novel Inhibitors for Α-Glucosidase, Bioorganic Chemistry (2022)